NASDAQ:EPIX ESSA Pharma (EPIX) Stock Forecast, Price & News $3.05 +0.06 (+2.01%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.94▼$3.0550-Day Range$2.60▼$3.1552-Week Range$1.40▼$5.38Volume20,583 shsAverage Volume38,210 shsMarket Capitalization$134.47 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ESSA Pharma MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside457.4% Upside$17.00 Price TargetShort InterestHealthy0.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.75) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsMedical Sector865th out of 983 stocksPharmaceutical Preparations Industry434th out of 486 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, ESSA Pharma has a forecasted upside of 457.4% from its current price of $3.05.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.90% of the float of ESSA Pharma has been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ESSA Pharma has recently decreased by 11.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EPIX. Previous Next 0.9 News and Social Media Coverage News SentimentESSA Pharma has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ESSA Pharma this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.75) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ESSA Pharma (NASDAQ:EPIX) StockESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EPIX Stock News HeadlinesJune 1, 2023 | finance.yahoo.comESSA Pharma to Present at 2023 Jefferies Healthcare ConferenceMay 24, 2023 | finance.yahoo.comWe're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash WiselyJune 3, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 18, 2023 | finance.yahoo.comEPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide…May 11, 2023 | finance.yahoo.comESSA Pharma to Present at JMP Securities Life Sciences ConferenceMay 9, 2023 | msn.comESSA Pharma: Q2 Earnings InsightsMay 9, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023April 18, 2023 | finance.yahoo.comESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceJune 3, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.April 15, 2023 | ca.finance.yahoo.comESSA Pharma Inc. (EPIX)April 12, 2023 | finance.yahoo.comESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate CancerMarch 8, 2023 | finance.yahoo.comESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 7, 2023 | finance.yahoo.comESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measuresFebruary 23, 2023 | finance.yahoo.comEPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…February 7, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022February 2, 2023 | finance.yahoo.comESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology ConferenceJanuary 25, 2023 | finance.yahoo.comA Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)December 15, 2022 | finance.yahoo.comWe're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn RateDecember 13, 2022 | msn.comESSA Pharma GAAP EPS of -$0.14December 13, 2022 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022November 15, 2022 | finance.yahoo.comEPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide…November 10, 2022 | finance.yahoo.comESSA Pharma to Participate in Two Upcoming Investor ConferencesOctober 31, 2022 | finance.yahoo.comJ&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatmentOctober 31, 2022 | finance.yahoo.comESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer TrialsOctober 26, 2022 | barrons.com(PR) ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR SymposiumOctober 26, 2022 | finance.yahoo.comUpdated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific RetreatSeptember 21, 2022 | finance.yahoo.comESSA Pharma Appoints Philip Kantoff to its Board of DirectorsSee More Headlines EPIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPIX Company Calendar Last Earnings5/09/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$17.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+457.4%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17.63% Return on Assets-17.32% Debt Debt-to-Equity RatioN/A Current Ratio73.64 Quick Ratio73.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.55 per share Price / Book0.86Miscellaneous Outstanding Shares44,090,000Free Float38,801,000Market Cap$134.47 million OptionableNot Optionable Beta2.09 Key ExecutivesDr. David Ross Parkinson M.D. (Age 73)Pres, CEO & Director Comp: $829.56kMr. David S. Wood C.M.A. (Age 66)CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer Comp: $532.35kMr. Peter A. Virsik M.B.A. (Age 52)M.S., Exec. VP & COO Comp: $646.75kDr. Alessandra Cesano M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $620.81kChandtip ChandhasinExec.Erica OsbourneExec.Erin RudsinskiExec.Loleta HarrisExec.Neil ThaparExec.Nkengyal BarberExec.More ExecutivesKey CompetitorsGalera TherapeuticsNASDAQ:GRTXIncannex HealthcareNASDAQ:IXHLAffimedNASDAQ:AFMDCelularityNASDAQ:CELUInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 50,955 shares on 5/18/2023Ownership: 0.135%Ally Bridge Group NY LLCSold 574,972 shares on 5/16/2023Ownership: 0.537%Susquehanna International Group LLPBought 41,900 shares on 5/16/2023Ownership: 0.000%Two Sigma Advisers LPBought 51,700 shares on 5/15/2023Ownership: 0.508%Two Sigma Investments LPSold 41,941 shares on 5/15/2023Ownership: 0.112%View All Insider TransactionsView All Institutional Transactions EPIX Stock - Frequently Asked Questions What is ESSA Pharma's stock price forecast for 2023? 0 Wall Street research analysts have issued 12 month price targets for ESSA Pharma's stock. Their EPIX share price forecasts range from $17.00 to $17.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 457.4% from the stock's current price. View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts. How have EPIX shares performed in 2023? ESSA Pharma's stock was trading at $2.52 at the beginning of 2023. Since then, EPIX stock has increased by 21.0% and is now trading at $3.05. View the best growth stocks for 2023 here. Are investors shorting ESSA Pharma? ESSA Pharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 171,000 shares, a decrease of 11.2% from the April 30th total of 192,600 shares. Based on an average trading volume of 75,600 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.9% of the shares of the stock are sold short. View ESSA Pharma's Short Interest. When is ESSA Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our EPIX earnings forecast. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX). What is ESSA Pharma's stock symbol? ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX." Who are ESSA Pharma's major shareholders? ESSA Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.81%), Ally Bridge Group NY LLC (0.54%), Two Sigma Advisers LP (0.51%), Susquehanna International Group LLP (0.00%), JPMorgan Chase & Co. (0.14%) and Two Sigma Investments LP (0.11%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech. View institutional ownership trends. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ESSA Pharma's stock price today? One share of EPIX stock can currently be purchased for approximately $3.05. How much money does ESSA Pharma make? ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $134.47 million. The company earns $-35,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. How can I contact ESSA Pharma? ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for the company is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080. This page (NASDAQ:EPIX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.